Jasper Completes IgAN Cohort Enrollment; Adds FSGS Cohort, Data Due Year-End
JSPR sits 59% above its 52-week low of $0.315.
Summary
Jasper completed enrollment of the 18-patient IgAN cohort of its Phase 2 study of vensobafusp alfa, with initial data due by year-end 2026, and added an FSGS cohort expected to dose its first patients in Q1 2027.
Key Events · Product Development and Regulatory · JSPR
-
IgAN Cohort Enrollment Complete
All 18 IgAN patients enrolled in Stage 1 of the Phase 2 basket study of vensobafusp alfa across three dosing cohorts (Q2W, Q4W, Q8W; n=6 each).
-
Year-End 2026 Data Readout
Initial Stage 1 safety, tolerability and efficacy data in IgAN are expected by year-end 2026.
-
FSGS Cohort Added
Jasper accelerated a new FSGS cohort in the same basket study, with first patients anticipated to be dosed in Q1 2027.
-
Listing and Financing Overhang
The clinical update lands amid a going-concern warning, a second Nasdaq deficiency notice with a November 30 deadline, a pending reverse-split vote, and a 284-million-share PIPE resale registration filed 2026-10-14.
Analysis · JSPR · Life Sciences
Jasper hit its enrollment target for the 18-patient IgAN cohort of the Phase 2 basket study of vensobafusp alfa (KP104) on schedule, and initial Stage 1 data are expected by year-end 2026. The company also accelerated a new FSGS cohort, with first patients anticipated to be dosed in Q1 2027. For a clinical-stage company whose lead complement asset is the core of its pipeline, a clean enrollment read is a de-risking step and the year-end data readout is the next hard milestone. The context is strained: a going-concern warning, a second Nasdaq deficiency notice with a November 30 deadline, a pending reverse-split vote, and a 284-million-share PIPE resale registration filed yesterday. Positive clinical execution does not fix the balance-sheet or listing problems, but it keeps the asset story intact while those are resolved.
How filings like this one have moved
In the 30 days to Oct 30, 2026, 30.7% of the 1581 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JSPR was trading at $0.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.7M. The 52-week trading range was $0.32 to $2.69. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.